Author: claimsbot

What is claimed:

1. A filtration funnel with integral prefilter comprising:
a funnel comprising a reservoir for holding unfiltered fluid therein and an outlet,
a final filter disposed between said reservoir and said outlet, said final filter sealed to said funnel to prevent unfiltered fluid from flowing between said final filter and said outlet, with the downstream side of said final filter in fluid flow communication with said outlet,
one or more prefilters disposed between said reservoir and the upstream side of said final filter,
a seal ring disposed above said one or more prefilters, said seal ring sealed to said funnel, with the bottom surface of said seal ring pressing against the outer periphery of the upstream surface of said one or more prefilters, thereby sealing said one or more prefilters to said funnel with a non-absolute seal, thereby causing said unfiltered fluid to flow through said one or more prefilters before flowing through said final filter, thereby increasing the volume of fluid that the filtration funnel can filter.
2. The filtration funnel of claim 1 wherein said final filter is a microporous filter.
3. The filtration funnel of claim 2 wherein the pore size of said microporous filter is less than or equal to 1.5 m.
4. The filtration funnel of claim 3 wherein said at least one prefilter contains a first prefilter, said first prefilter disposed above said final filter, said first prefilter having an open pore size, thereby functioning as a flow distributor.
5. The filtration funnel of claim 4 wherein said at least one prefilter contains a second prefilter, said second prefilter disposed above said first prefilter, said second prefilter being a microporous filter with a pore size greater than that of said final filter.
6. The filtration funnel of claim 5 wherein said at least one prefilter contains a third prefilter, said third prefilter disposed above said second prefilter, said third prefilter being a depth filter capable of protecting said second prefilter.
7. The filtration funnel of claim 1 wherein said at least one prefilter contains a first prefilter, said first prefilter disposed above said final filter, said first prefilter being a depth filter capable of protecting said final filter.
8. The filtration funnel of claim 1 wherein said seal ring is sealed to said funnel with a press fit between the outer edge of said seal ring, and the inner wall of said funnel.
9. The filtration funnel of claim 1 wherein said filtration funnel is disposable.
10. A filtration apparatus for filtering a fluid comprising:
a filtration funnel with integral prefilter comprising:
a funnel comprising a reservoir for holding unfiltered fluid therein and an outlet,
a final filter disposed between said reservoir and said outlet, said final filter sealed to said funnel to prevent unfiltered fluid from flowing between said final filter and said outlet, with the downstream side of said final filter in fluid flow communication with said outlet,
one or more prefilters disposed between said reservoir and the upstream side of said final filter,
a seal ring disposed above said one or more prefilters, said seal ring sealed to said funnel, with the bottom surface of said seal ring pressing against the outer periphery of the upstream surface of said one or more prefilters, thereby sealing said one or more prefilters to said funnel with a non-absolute seal, thereby causing said unfiltered fluid to flow through said one or more prefilters before flowing through said final filter, thereby increasing the volume of fluid that the filtration funnel can filter,

a means to collect filtered fluid from said outlet of said funnel,
a means to apply a differential pressure between the top of said unfiltered fluid in said reservoir, and said outlet of said funnel.
11. The filtration apparatus of claim 10 wherein the means to collect filtered fluid from the outlet of said funnel is a bottle disposed below said funnel, with the outlet of said funnel in fluid flow communication with the interior of said bottle.
12. The filtration apparatus of claim 11 wherein the top of said unfiltered fluid in said reservoir is vented to atmosphere, and wherein a vacuum is applied to the interior of said bottle, thereby creating a differential pressure between the top of said unfiltered fluid in said reservoir, and said outlet of said funnel, thereby sucking said unfiltered fluid from said reservoir, through said at least one prefilter, through said final filter, through said outlet, into said bottle.
13. The filtration funnel of claim 12 wherein said final filter is a microporous filter.
14. The filtration funnel of claim 13 wherein the pore size of said microporous filter is less than or equal to 1.5 m.
15. The filtration funnel of claim 14 wherein said at least one prefilter contains a first prefilter, said first prefilter disposed above said final filter, said first prefilter having an open pore size, thereby functioning as a flow distributor.
16. The filtration funnel of claim 15 wherein said at least one prefilter contains a second prefilter, said second prefilter disposed above said first prefilter, said second prefilter being a microporous filter with a pore size greater than that of said final filter.
17. The filtration funnel of claim 16 wherein said at least one prefilter contains a third prefilter, said third prefilter disposed above said second prefilter, said third prefilter being a depth filter capable of protecting said second prefilter.
18. The filtration funnel of claim 13 wherein said at least one prefilter contains a first prefilter, said first prefilter disposed above said final filter, said first prefilter being a depth filter capable of protecting said final filter.
19. The filtration apparatus of claim 1 1 wherein the top of said unfiltered fluid in said reservoir is pressurized, and wherein the interior of said bottle is vented to atmosphere, thereby creating a differential pressure between the top of said unfiltered fluid in said reservoir, and said outlet of said funnel, thereby forcing said unfiltered fluid from said reservoir, through said at least one prefilter, through said final filter, through said outlet, into said bottle.
20. The filtration apparatus of claim 10 wherein said filtration apparatus is disposable.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A processor-implemented method of tracing a traitor from a circumvention device, the circumvention device comprising a set of compromised device keys obtained from the traitor, the method comprising:
generating a hypothesized model on a hypothesized set of device keys that models a hypothesis that the circumvention device comprises the hypothesized set of device keys, wherein the hypothesized model is represented by any of a tabular form, a function, a graphical model, and a Bayesian network;
passing the hypothesized model to a subset tracing method to identify a compromised device key, the subset tracing method comprising;
generating a circumvention device model that models a behavior of a circumvention device, wherein
the circumvention device model comprises a set of tests from which tests are selected, a set of key sets comprising one key set for each of the set of tests, and a probability for each of the key sets indicating a probability that the circumvention device will play the one of the set of tests associated with the key set: and
the circumvention device model is represented by any of a tabular form, a function, a graphical model, and a Bayesian network:
selecting a test, utilizing gained informativeness information and based on the hypothesized model and the circumvention device model, to apply to the circumvention device, wherein the test comprises a forensic media key block that obtains informative data about the compromised device key by observing the response:
receiving a response from the circumvention device, the response indicating a success of the test in playing a protected content on the circumvention device:
updating the hypothesized model using the received response, incorporating the response into the hypothesized model using any of a graphic model or a Bayesian network, and using the selected test, a current version of the hypothesized model, and a current version of the circumvention device model for selecting at least one test that identifies the compromised device keys obtained from the traitor: and
testing the hypothesized model to determine the strength of the belief that the compromised device key is contained in the circumvention device

removing the compromised key, adding new keys to the hypothesized set of keys and updating the hypothesized model, wherein updating the hypothesized model comprises:
generating the probabilities of the newly added keys being in the circumvention device: and
applying an inference logic using any of a variable elimination, a belief propagation, and a junction tree, wherein the inference logic utilizes an approximation algorithm comprising any of a sample based approximation, a partition-based approximation, and a loopy belief propagation:

iteratively detecting additional compromised device keys from the set of compromised device keys, until substantially all the compromised device keys in the set of compromised device keys are identified so as to disable the circumvention device; and
creating a media key block MKB on the hypothesized set of device keys that disables the circumvention device.
2-37. (canceled)

1. A method for detecting multidrug resistance or multidrug resistance potential in a test neoplastic cell, comprising:
a) measuring a level of cell surface-expressed vimentin protein in the test neoplastic cell of a given origin or cell type, and
b) comparing the level of cell surface-expressed vimentin protein in the test neoplastic cell to the level of cell surface-expressed vimentin in a nonresistant neoplastic cell of the same origin or cell type,
wherein the test neoplastic cell is multidrug resistant or has multidrug resistance potential if the level of cell surface-expressed vimentin in the test neoplastic cell is greater than the level of cell surface-expressed vimentin in the nonresistant neoplastic cell of the same given origin or cell type.
2. The method of claim 1, wherein measuring the level of cell surface-expressed vimentin in the test neoplastic cell comprises isolating a cytoplasmic membrane fraction from the cell and measuring the level of vimentin in the cytoplasmic membrane fraction.
3. The method of claim 1, wherein measuring the level of cell surface-expressed vimentin in the test neoplastic cell comprises contacting said cell with an anti-vimentin antibody and measuring the level of antibody bound to cell surface vimentin.
4. The method of claim 3, wherein measuring the level of antibody bound to cell surface vimentin is by immunofluorescence emission.
5. The method of claim 3, wherein measuring the level of antibody bound to cell surface vimentin is by radiolabel.
6. The method of claim 1, wherein the test neoplastic cell is selected from the group consisting of a promyleocytic leukemia cell, a T lymphoblastoid cell, a breast epithelial cell, and an ovarian cell.
7. The method of claim 1, wherein the nonresistant neoplastic cell is from a drug-sensitive cell line selected from the group consisting of HL60, NB4, CEM, HSB2 Molt4, MCF-7, MDA, SKOV-3, and 2008.
8. The method of claim 1, wherein the test neoplastic cell is selected from the group consisting of a lymphoma cell, a melanoma cell, a sarcoma cell, a leukemia cell, a retinoblastoma cell, a hepatoma cell, a myeloma cell, a glioma cell, a mesothelioma cell, and a carcinoma cell.
9. The method of claim 1, wherein the test neoplastic cell is from a tissue selected from the group consisting of blood, bone marrow, spleen, lymph node, liver, thymus, kidney, brain, skin, gastrointestinal tract, eye, breast, prostate, and ovary.
10. A method for detecting a multidrug resistant cell in a patient comprising:
(a) administering to the patient, a vimentin binding agent operably linked to a detectable label; and
(b) detecting the label operably linked to the vimentin binding agent,
wherein the vimentin binding agent specifically binds to cell surface-expressed vimentin present on a multidrug resistant cell in the patient.
11. The method of claim 10, wherein the vimentin binding agent is an antibody or fragment thereof.
12. The method of claim 10, wherein the vimentin binding agent is selected from the group consisting of modified LDL, NLK1 protein, vimentin, desmin, glial fibrillary acidic protein, and peripherin, fimbrin, RhoA-binding kinase alpha, and protein phosphatase 2A.
13. The method of claim 10, wherein the vimentin binding agent is selected from the group consisting of natural ligands, synthetic small molecules, chemicals, nucleic acids, peptides, proteins, and antibodies.
14. The method of claim 10, wherein the detectable label is selected from the group consisting of fluorophores, chemical dyes, radioactive compounds, chemoluminescent compounds, magnetic compounds, paramagnetic compounds, promagnetic compounds, enzymes that yield a colored product, enzymes that yield a chemoluminescent product, and enzymes that yield a magnetic product.
15. The method of claim 14, wherein the multidrug resistant cell is a neoplastic cell.
16. The method of claim 15, wherein the neoplastic cell is selected from the group consisting of a breast cancer cell, an ovarian cancer cell, a myeloma cancer cell, a lymphoma cancer cell, a melanoma cancer cell, a sarcoma cancer cell, a leukemia cancer cell, a retinoblastoma cancer cell, a hepatoma cancer cell, a glioma cancer cell, a mesothelioma cancer cell, and a carcinoma cancer cell.
17. The method of claim 15, wherein the neoplastic cell is selected from the group consisting of a promyleocytic leukemia cell, a T lymphoblastoid cell, a breast epithelial cell, and an ovarian cell.
18. The method of claim 10, wherein the patient is a human.
19. The method of claim 18, wherein the patient is suffering from a disease or disorder caused by the presence of the multidrug resistant cell.
20. A kit for diagnosing or detecting multidrug resistance in a test neoplastic cell comprising:
a) a first probe for the detection of vimentin; and
b) a second probe for the detection of a multidrug resistance marker selected from the group consisting of nucleophosmin and HSC70.
21. A kit for diagnosing or detecting multidrug resistance in a test neoplastic cell comprising:
a) a first probe for the detection of vimentin; and
b) a second probe for the detection of a marker selected from the group consisting of MDR1, MDR3, MRP1, MRP5, and LRP.
22. The kit of claim 20 or 21, wherein the probe for detecting vimentin is an anti-vimentin antibody.
23. The kit of claim 20 or 21, wherein the probe for detecting vimentin is a vimentin ligand selected from the group consisting of LDL, NLK1 protein, vimentin, desmin, glial fibrillary acidic protein, and peripherin, fimbrin, RhoA-binding kinase alpha, and protein phosphatase 2A.
24. The kit of claim 20, wherein the second probe is selected from the group consisting of a nucleophosmin antibody and an HSC70 antibody.
25. The kit of claim 20, wherein the second probe is selected from the group consisting of a nucleophosmin ligand and an HSC70 ligand.
26. The kit of claim 20 or 21, wherein the first probe detects vimentin present on the surface of the test neoplastic cell.
27. The kit of claim 20 or 21, wherein the second probe detects a marker present of the surface of the test neoplastic cell.
28. The kit of claim 21, wherein the second probe is selected from the group consisting of: an MDR1 antibody, an MDR3 antibody, an MRP1 antibody, an MRP3 antibody, and an LRP antibody.
29. A cell surface vimentin in situ detection probe for the detection of cell surface vimentin in a patient, comprising a vimentin binding component and a detectable label for detection in situ.
30. The cell surface vimentin in situ detection probe of claim 29, wherein the vimentin binding component is an antibody.
31. The cell surface vimentin in situ detection probe of claim 29, wherein the detectable label is Technetium.
32. A cell surface vimentin-targeted agent for treating or preventing a multi-drug resistant neoplasm, comprising a vimentin binding component and a therapeutic component, wherein the vimentin binding component targets the therapeutic component to the multi-drug resistant neoplasm and thereby treats the multi-drug resistant neoplasm.
33. The agent of claim 32, wherein the vimentin binding component is an anti-vimentin antibody.
34. The agent of claim 32, wherein the vimentin binding component is selected from the group consisting of LDL, NLK1 protein, vimentin, desmin, glial fibrillary acidic protein, peripherin, fimbrin, RhoA-binding kinase alpha, and protein phosphatase 2A.
35. The agent of claim 32, wherein said vimentin binding component is selected from the group consisting of natural ligands, synthetic small molecules, chemicals, nucleic acids, peptides, proteins, antibodies, and vimentin binding fragments thereof.
36. The agent of claim 32, wherein the therapeutic component is selected from the group consisting of Actinomycin, Adriamycin, Altretamine, Asparaginase, Bleomycin, Busulfan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Docetaxel, Doxorubicin, Epoetin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Lomustine, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Paclitaxel, Pentostatin, Procarbazine, Taxol, Teniposide, Topotecan, Vinblastine, Vincristine, and Vinorelbine.
37. The agent of claim 32, wherein the therapeutic component is in a liposome formulation.
38. The agent of claim 32, wherein the therapeutic component is a radioisotope.
39. The agent of claim 38, wherein the radioisotope is selected from the group consisting of 90Y, 125I, 131I, 211At, and 213Bi.
40. The agent of claim 32, wherein the therapeutic component is a toxin capable of killing or inducing the killing of the targeted multi-drug resistant neoplastic cell.
41. The agent of claim 40, wherein the toxin is selected from the group consisting of a Pseudomonas exotoxin, a diphtheria toxin, a plant ricin toxin, a plant abrin toxin, a plant saporin toxin, a plant gelonin toxin, and pokeweed antiviral protein.
42. The agent of any of claims 32-41, wherein the vimentin binding component binds to the surface of the target cell and the therapeutic element is internalized and arrests growth of the cell, compromises viability of the cell or kills the cell.
43. A vaccine for treating or preventing a multi-drug resistant neoplasm, comprising a vimentin polypeptide, or vimentin polypeptide subsequence thereof, and at least one pharmaceutically acceptable vaccine component.
44. The vaccine of claim 43, wherein the vimentin polypeptide or polypeptide subsequence is a human vimentin polypeptide sequence of SEQ ID NO.: 1.
45. The vaccine of claim 43, wherein the vimentin polypeptide subsequence is at least eight amino acids long.
46. The vaccine of claim 45, wherein the vimentin polypeptide subsequence comprises a hapten.
47. The vaccine of claim 43, wherein the pharmaceutically acceptable vaccine component is an adjuvant.
48. The vaccine of claim 47, wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, calcium phosphate, oil emulsion, a bacterial product, whole inactivated bacteria, an endotoxins, cholesterol, a fatty acid, an aliphatic amine, a paraffinic compound, a vegetable oil, monophosphoryl lipid A, a saponin, and squalene.
49. A method of treating or preventing a multidrug resistant neoplasm in a subject comprising administering a cell surface vimentin-targeted therapeutic agent of any of claims 32-41.
50. The method of claim 49, wherein the neoplasm is selected from the group consisting of a breast cancer, an ovarian cancer, a myeloma, a lymphoma, a melanoma, a sarcoma, a leukemia, a retinoblastoma, a hepatoma, a glioma, a mesothelioma, and a carcinoma.
51. The method of claim 49, wherein the subject is a human patient.
52. The method of claim 51, wherein the human patient is suffering from a disease or disorder caused by the presence of the multi-drug resistant cell.
53. The method of claim 49, wherein the neoplasm is from a tissue selected from the group consisting of blood, bone marrow, spleen, lymph node, liver, thymus, kidney, brain, skin, gastrointestinal tract, eye, breast, prostate, and ovary.
54. A method of treating or preventing a multidrug resistant neoplasm in a subject comprising administering a vimentin vaccine of any of claims 43-48.
55. The method of claim 54, wherein the neoplasm is selected from the group consisting of a breast cancer, an ovarian cancer, a myeloma, a lymphoma, a melanoma, a sarcoma, a leukemia, a retinoblastoma, a hepatoma, a glioma, a mesothelioma, and a carcinoma.
56. The method of claim 54, wherein the subject is a human patient.
57. The method of claim 56, wherein the human patient is suffering from a disease or disorder caused by the presence of the multi-drug resistant cell.
58. The method of claim 54, wherein the neoplasm is from a tissue selected from the group consisting of blood, bone marrow, spleen, lymph node, liver, thymus, kidney, brain, skin, gastrointestinal tract, eye, breast, prostate, and ovary.
59. A method for detecting whether a test cell is neoplastic comprising a) measuring a level of cell surface-expressed vimentin protein in the test cell of a given origin or cell type, and
b) comparing the level of cell surface-expressed vimentin protein in the test cell to the level of cell surface-expressed vimentin in a normeoplastic cell of the same origin or cell type,
wherein the test cell is neoplastic if the level of cell surface-expressed vimentin in the test cell is greater than the level of cell surface-expressed vimentin in the normeoplastic cell of the same origin or cell type.
60. The method of claim 59, wherein measuring the level of cell surface-expressed vimentin in the test cell comprises isolating a cytoplasmic membrane fraction from the cell and measuring the level of vimentin in the cytoplasmic membrane fraction.
61. The method of claim 59, wherein measuring the level of cell surface-expressed vimentin in the test cell comprises contacting said cell with an anti-vimentin antibody and measuring the level of antibody bound to cell surface vimentin.
62. The method of claim 61, wherein measuring the level of antibody bound to cell surface vimentin is by immunofluorescence emission.
63. The method of claim 61, wherein measuring the level of antibody bound to cell surface vimentin is by radiolabel.
64. The method of claim 59, wherein the test cell is from a tissue selected from the group consisting of blood, bone marrow, spleen, lymph node, liver, thymus, kidney, brain, skin, gastrointestinal tract, eye, breast, prostate, and ovary.
65. The method of claim 59, wherein the normeoplastic cell is from a tissue selected from the group consisting of blood, bone marrow, spleen, lymph node, liver, thymus, kidney, brain, skin, gastrointestinal tract, eye, breast, prostate, and ovary.
66. A method for detecting a neoplastic cell in a patient comprising:
(a) administering to the patient, a vimentin binding agent operably linked to a detectable label; and
(b) detecting the label operably linked to the vimentin binding agent,
wherein the vimentin binding agent specifically binds to cell surface-expressed vimentin present on a neoplastic cell in the patient.
67. The method of claim 66, wherein the vimentin binding agent is an antibody or fragment thereof.
68. The method of claim 66, wherein the vimentin binding agent is selected from the group consisting of modified LDL, NLK1 protein, vimentin, desmin, glial fibrillary acidic protein, and peripherin, fimbrin, RhoA-binding kinase alpha, and protein phosphatase 2A.
69. The method of claim 66, wherein the vimentin binding agent is selected from the group consisting of natural ligands, synthetic small molecules, chemicals, nucleic acids, peptides, proteins, antibodies, and fragments thereof.
70. The method of claim 66, wherein the detectable label is selected from the group consisting of fluorophores, chemical dyes, radioactive compounds, chemoluminescent compounds, magnetic compounds, paramagnetic compounds, promagnetic compounds, enzymes that yield a colored product, enzymes that yield a chemoluminescent product, and enzymes that yield a magnetic product.
71. The method of claim 66, wherein the neoplastic cell is selected from the group consisting of a breast cancer cell, an ovarian cancer cell, a myeloma cancer cell, a lymphoma cancer cell, a melanoma cancer cell, a sarcoma cancer cell, a leukemia cancer cell, a retinoblastoma cancer cell, a hepatoma cancer cell, a glioma cancer cell, a mesothelioma cancer cell, and a carcinoma cancer cell.
72. The method of claim 66, wherein the neoplastic cell is selected from the group consisting of a promyleocytic leukemia cell, a T lymphoblastoid cell, a breast epithelial cell, and an ovarian cell.
73. The method of claim 66, wherein the patient is a human.
74. The method of claim 73, wherein the patient is suffering from a disease or disorder caused by the presence of the neoplastic cell.
75. A kit for diagnosing or detecting neoplasia, comprising:
a) a first probe for the detection of vimentin; and
b) a second probe for the detection of a neoplasia marker selected from the group consisting of nucleophosmin and HSC70.
76. The kit of claim 75, wherein the probe for detecting vimentin is an anti-vimentin antibody or binding fragment thereof.
77. The kit of claim 75, wherein the probe for detecting vimentin is a vimentin ligand selected from the group consisting of LDL, NLK1 protein, vimentin, desmin, glial fibrillary acidic protein, and peripherin, fimbrin, RhoA-binding kinase alpha, and protein phosphatase 2A.
78. The kit of claim 75, wherein the second probe is selected from the group consisting of a nucleophosmin antibody and an HSC70 antibody.
79. The kit of claim 75, wherein the second probe is selected from the group consisting of a nucleophosmin ligand and an HSC70 ligand.
80. The kit of claim 75, wherein the first probe detects vimentin present on the surface of the test cell if it is neoplastic.
81. The kit of claim 75, wherein the second probe detects a marker present of the surface of the test cell if it is neoplastic.
82. A cell surface vimentin-targeted agent for treating a cancerous neoplastic cell growth comprising a vimentin binding component and a therapeutic component, wherein the vimentin binding component targets the therapeutic component to the neoplastic cell growth and thereby treats the cancer.
83. The agent of claim 82, wherein the vimentin binding component is an anti-vimentin antibody.
84. The agent of claim 82, wherein the vimentin binding component is selected from the group consisting of LDL, NLK1 protein, vimentin, desmin, glial fibrillary acidic protein, and peripherin, fimbrin, RhoA-binding kinase alpha, and protein phosphatase 2A.
85. The agent of claim 82, wherein said vimentin binding component is selected from the group consisting of natural ligands, synthetic small molecules, chemicals, nucleic acids, peptides, proteins, antibodies, and vimentin binding fragments thereof.
86. The agent of claim 82, wherein the therapeutic component is selected from the group consisting of Actinomycin, Adriamycin, Altretamine, Asparaginase, Bleomycin, Busulfan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Cyclophosphamide, Cytarabine, Dacarbazine, Dactinomycin, Daunorubicin, Docetaxel, Doxorubicin, Epoetin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Lomustine, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Paclitaxel, Pentostatin, Procarbazine, Taxol, Teniposide, Topotecan, Vinblastine, Vincristine, and Vinorelbine and combinations thereof.
87. The agent of claim 82, wherein the therapeutic component is in a liposome formulation.
88. The agent of claim 82, wherein the therapeutic component is a radioisotope.
89. The agent of claim 88, wherein the radioisotope is selected from the group consisting of 90Y, 111In, 125I, 131I, 211At, and 213Bi.
90. The agent of claim 82, wherein the therapeutic component is a toxin capable of killing or inducing the killing of the targeted neoplastic cell.
91. The agent of claim 90, wherein the toxin is selected from the group consisting of a Pseudomonas exotoxin, a diphtheria toxin, a plant ricin toxin, a plant abrin toxin, a plant saporin toxin, a plant gelonin toxin, and pokeweed antiviral protein.
92. The agent of any of claims 82-91, wherein the vimentin binding component binds to the surface of the target cell and the therapeutic element is internalized and arrests growth of the cell, compromises viability of the cell, or kills the cell.
93. A vaccine for treating or preventing a neoplasm comprising a vimentin polypeptide, or vimentin polypeptide subsequence thereof, and at least one pharmaceutically acceptable vaccine component.
94. The vaccine of claim 93, wherein the vimentin polypeptide or polypeptide subsequence is a human vimentin polypeptide sequence set forth in SEQ ID NO.: 1.
95. The vaccine of claim 93, wherein the vimentin polypeptide subsequence is at least eight amino acids long.
96. The vaccine of claim 95, wherein the vimentin polypeptide subsequence comprises a hapten.
97. The vaccine of claim 93, wherein the pharmaceutically acceptable vaccine component is an adjuvant.
98. The vaccine of claim 97, wherein the adjuvant is selected from the group consisting of aluminum hydroxide, aluminum phosphate, calcium phosphate, oil emulsion, a bacterial product, whole inactivated bacteria, an endotoxins, cholesterol, a fatty acid, an aliphatic amine, a paraffinic compound, a vegetable oil, monophosphoryl lipid A, a saponin, and squalene.
99. A method of treating or preventing a neoplasm in a subject comprising administering a cell surface vimentin-targeted therapeutic agent of any of claims 82-91.
100. The method of claim 99, wherein the neoplasm is selected from the group consisting of a breast cancer, an ovarian cancer, a myeloma, a lymphoma, a melanoma, a sarcoma, a leukemia, a retinoblastoma, a hepatoma, a glioma, a mesothelioma, and a carcinoma.
101. The method of claim 99, wherein the subject is a human patient.
102. The method of claim 101, wherein said human patient is suffering from a disease or disorder caused by the presence of the multi-drug resistant cell.
103. The method of claim 99, wherein the neoplasm is from a tissue selected from the group consisting of blood, bone marrow, spleen, lymph node, liver, thymus, kidney, brain, skin, gastrointestinal tract, eye, breast, prostate and ovary.
104. A method of treating or preventing a neoplasm in a subject comprising administering a vimentin vaccine of any of claims 93-98.
105. The method of claim 104, wherein the neoplasm is selected from the group consisting of a breast cancer, an ovarian cancer, a myeloma, a lymphoma, a melanoma, a sarcoma, a leukemia, a retinoblastoma, a hepatoma, a glioma, a mesothelioma, and a carcinoma.
106. The method of claim 104, wherein said subject is a human patient.
107. The method of claim 106, wherein said human patient is suffering from a disease or disorder caused by the presence of the neoplastic cell.
108. The method of claim 104, wherein the neoplasm is from a tissue selected from the group consisting of blood, bone marrow, spleen, lymph node, liver, thymus, kidney, brain, skin, gastrointestinal tract, eye, breast, prostate, and ovary.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1 A storage system, comprising:
a plurality of file servers;
a plurality of file systems to be mounted on said file servers;
a storage device for providing a storage area to said file servers; and
a management module for managing the access of a client to said file systems mounted on said file servers;
wherein said storage system provides a shared file system having the same namespace to said client accessing said file systems; and
wherein said management module, includes:
a first information table storing the correspondence of said file system and said file server mounting said file system; and
a second information table storing the correspondence of said file system and the frequency of access by said client to said file system.
2. The storage system according to claim 1, wherein said management module updates said access frequency of said second information table each time said client accesses said file system.
3. The storage system according to claim 1, wherein said management module totals said second information table per said client and decides said file system and another file server to become the destination of said file system so that the number of accesses to said file system from a specific client is reduced.
4. The storage system according to claim 3, wherein said management module includes a program for mounting said file system on said another file server.
5. The storage system according to claim 3, wherein said management module calculates the combination of said file system in which said number of accesses is reduced and the file server to which said file system is migrated, and outputs the result thereof.
6. The storage system according to claim 1, wherein said management module totals said second information table per said client, and decides another server to which a specific client should be connected so that the number of accesses to said file system from said specific client is reduced.
7. The storage system according to claim 6, wherein said management module includes a program for changing the access path from said client to said another file server so that said client is connected to said another file server.
8. The storage system according to claim 3, wherein said management module decides the combination of said file system and said another file server so that the CPU utilization factor of said another file server to which said file system is migrated will decrease.
9. The storage system according to claim 3, wherein said management module decides the combination of said file system and said another file server so that the IO load of said another file server to which said file system is migrated will decrease.
10. The storage system according to claim 3, wherein said management module decides the combination of said file system and said another file server so that the network load of said another file server to which said file system is migrated will decrease.
11. A storage system, comprising:
a plurality of nodes;
a plurality of resources to be mounted on said nodes;
a storage device for providing a storage area to said resources;
a management module for managing the access of a client to said resources mounted on said nodes;
a table for managing the status of said client accessing said resources; and
a management module for referring to said table, deciding the node to which said resource is to be migrated, and reducing the number of trials until said client accesses its target resource.
12. The storage system according to claim 11, wherein said node is a file server, and said resource is a file system, directory or a file.
13. A method of controlling a storage system comprising a plurality of file servers; a plurality of file systems to be mounted on said file servers; a storage device for providing a storage area to said file servers; and a management module for managing the access of a client to said file systems mounted on said file servers; wherein said storage system provides a shared file system having the same namespace to said client accessing said file systems; and wherein said management module refers to a table for managing the status of said client accessing said file systems, decides said file server to which said file system is to be migrated, and reduces the number of trials until said client accesses its target file system.